Compositions for and method of treating acid-base disorders
The present disclosure provides, inter alia, pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. In certain embodiments, the pharmaceutical compositions contain nonabsorbable pharmaceutical composition and may be used, for example, to treat eubicarbonatemic metabolic acidosis.
1. A method of treating a patient with chronic kidney disease and eubicarbonatemic metabolic acidosis, wherein the method comprises oral administration of a nonabsorbable pharmaceutical composition comprising a proton-binding, crosslinked amine polymer comprising the residue of an amine corresponding to Formula 1:
wherein R1, R2 and R3 are independently hydrogen, hydrocarbyl, substituted hydrocarbyl provided, however, at least one of R1, R2 and R3 is other than hydrogen, the crosslinked amine polymer has an equilibrium swelling ratio in deionized water of about 5 or less, and the crosslinked amine polymer binds a molar ratio of chloride ions to interfering ions of at least 0.35:1, respectively, in an interfering ion buffer at 37° C. wherein (i) the interfering ions are phosphate ions and the interfering ion buffer is a buffered solution at pH 5.5 of 36 mM chloride and 20 mM phosphate or (ii) the interfering ions are phosphate, citrate and taurocholate ions (combined amount) and the interfering ion buffer is a buffered solution at pH 6.2 including 36 mM chloride, 7 mM phosphate, 1.5 mM citrate, and 5 mM taurocholate.
2. The method of claim 1 , wherein the method prevents the onset of chronic metabolic acidosis.
3. The method of claim 1 , wherein the method slows the progression of chronic kidney disease.
4. The method of claim 1 , wherein the method halts the progression of chronic kidney disease.
5. The method of claim 1 , wherein the patient is not yet in need for kidney replacement therapy (dialysis or transplant).
6. The method of claim 1 , wherein the patient has not yet reached end stage renal disease (“ESRD”).
7. The method of claim 1 , wherein the patient has a mGFR of at least 15 mL/min/1.73 m2.
8. The method of claim 1 , wherein the nonabsorbable pharmaceutical composition is characterized by a chloride ion binding capacity of at least 1 mEq/g in a SIB assay.
9. The method of claim 1 , wherein the nonabsorbable pharmaceutical composition is characterized by a chloride ion binding capacity of at least 1.5 mEq/g in a SIB assay.
10. The method of claim 1 , wherein the nonabsorbable pharmaceutical composition is characterized by a chloride ion binding capacity of at least 2 mEq/g in a SIB assay.
11. The method of claim 1 , wherein the ratio of the amount of bound chloride to bound phosphate in a SIB assay is at least 0.25:1, respectively.
12. The method of claim 1 , wherein the ratio of the amount of bound chloride to bound phosphate in a SIB assay is at least 0.5:1, respectively.
13. The method of claim 1 , wherein the ratio of the amount of bound chloride to bound phosphate in a SIB assay is at least 1:1, respectively.
14. The method of claim 1 , wherein the treatment with the nonabsorbable pharmaceutical composition does not have a clinically significant impact upon the serum or colon levels of a metabolically relevant species.
15. The method of claim 1 , wherein the subject has nephrolithiasis.
16. The method of claim 1 , wherein the subject has bone loss.
17. The method of claim 1 , wherein the subject has renal hypertrophy.
18. The method of claim 1 , wherein the patient is treated for at least one week.
19. The method of claim 1 , wherein the patient is treated for at least one month.
20. The method of claim 1 , wherein the patient is treated for at least six months.
21. The method of claim 1 , wherein the patient is treated for at least one year.